Octreotide is a cyclic octapeptide with one amino acid substitution. It has long-acting properties and is distributed within the microspheres which are made of a biodegradable glucose star polymer. Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with slow release properties. Octreotide substantially reduces and in many cases can normalize growth hormone levels in patients with acromegaly. The mean peak concentration of 2.8 ng/mL (100 mcg dose) was reached on day 1. In a mean hormone level of <2.5 ng/mL was observed in 66% receiving Sandostatin LAR® Depot. Over the course of the trials 42% of patients maintained mean growth hormone levels of <2.5 ng/mL + IGF-1 levels. In comparing the hormonal response in these patients, it was noted that patients receiving Sandostatin LAR® Depot had a greater decrease in the mean growth hormone level. Patients maintained mean growth hormone levels of <2.5 ng/mL + IGF-1 levels. In comparing the hormonal response in these patients, it was noted that patients receiving Sandostatin LAR® Depot had a greater decrease in the mean growth hormone level.

In blood, the distribution of octreotide into the erythrocytes was found to be negligible. In comparing the hormonal response in these patients, it was noted that patients receiving Sandostatin LAR® Depot had a greater decrease in the mean growth hormone level. Patients maintained mean growth hormone levels of <2.5 ng/mL + IGF-1 levels. In comparing the hormonal response in these patients, it was noted that patients receiving Sandostatin LAR® Depot had a greater decrease in the mean growth hormone level.

In comparing the hormonal response in these patients, it was noted that patients receiving Sandostatin LAR® Depot had a greater decrease in the mean growth hormone level. Patients maintained mean growth hormone levels of <2.5 ng/mL + IGF-1 levels. In comparing the hormonal response in these patients, it was noted that patients receiving Sandostatin LAR® Depot had a greater decrease in the mean growth hormone level.
In a clinical trial of craniopharyngioma, nausea, abdominal pain, and flatulence were reported in 37% and 25% of patients, respectively, in patients treated with Sandostatin LAR® Depot compared to 15% and 12% in patients treated with octreotide acetate for injectable suspension (see PRECAUTIONS). It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sandostatin LAR® Depot is administered to a nursing mother.

| Table 4                                                                 |
|---|---|
| **Adverse Events** | **Incidence** |
| **Allergic Reactions** | **<1%** |
| **Cardiac** | **5.6%** |
| **Gastrointestinal** | **29.8%** |
| **Hepatic** | **2.5%** |
| **Hematologic** | **5%** |
| **Nervous System** | **4%** |
| **Skin** | **2%** |
| **Urinary System** | **1.3%** |
| **Reproductive, Female** | **0.9%** |

**Adverse Events**

In patients with renal failure requiring dialysis, the half-life of octreotide may be increased, necessitating adjustment of the maintenance dosage (see CLINICAL PHARMACOLOGY and Pharmacokinetics of Octreotide Acetate).

**Storage**

For prolonged storage, Sandostatin LAR® Depot should be stored at refrigerated temperature (2°C to 8°C [36°F to 46°F]) and protected from light until the time of use. For immediate use, the drug suspension is stable for 5 minutes at room temperature (25°C to 30°C [77°F to 86°F]). Otherwise, adverse events (predominantly nausea and vomiting) may be delayed or prolonged.

**Dosage and Administration**

Sandoz Laboratories (Sandostatin LAR® Depot) (octreotide acetate for injectable suspension) must be administered subcutaneously or intramuscularly. It is not recommended for other routes of administration (see CLINICAL PHARMACOLOGY and Pharmacokinetics of Octreotide Acetate). Sandostatin LAR® Depot should be administered at dosages greater than or equal to 100 mcg per day. Two patients currently receiving Sandostatin® (octreotide acetate) Injection s.c. in Japan were switched to Sandostatin LAR® Depot, in each case after at least 2 weeks. Thereafter, patients who are considered "responders" to Sandostatin® s.c. and tolerates the drug may continue to receive Sandostatin LAR® Depot. The dosage regimen described under Table 4 below does not consider the dosage adjustments made after 2 weeks (see Table 4).

**Patients Currently Receiving Sandostatin® (octreotide acetate) Injection s.c.**

In patients receiving Sandostatin® (octreotide acetate) Injection s.c., in the majority of patients, the half-life of the drug was reduced when switching to Sandostatin LAR® Depot. The dosage regimen described under Table 4 below assumes that patients have not been switched (see Table 4).

| Table 5                                                                 |
|---|---|
| **Adverse Events** | **Incidence** |
| **Allergic Reactions** | **<1%** |
| **Cardiac** | **5.6%** |
| **Gastrointestinal** | **29.8%** |
| **Hepatic** | **2.5%** |
| **Hematologic** | **5%** |
| **Nervous System** | **4%** |
| **Skin** | **2%** |
| **Urinary System** | **1.3%** |
| **Reproductive, Female** | **0.9%** |

**Adverse Events**

In patients with renal failure requiring dialysis, the half-life of octreotide may be increased, necessitating adjustment of the maintenance dosage (see CLINICAL PHARMACOLOGY and Pharmacokinetics of Octreotide Acetate). Sandostatin LAR® Depot should be administered at dosages greater than or equal to 100 mcg per day. Two patients currently receiving Sandostatin® (octreotide acetate) Injection s.c. in Japan were switched to Sandostatin LAR® Depot, in each case after at least 2 weeks. Thereafter, patients who are considered "responders" to Sandostatin® s.c. and tolerates the drug may continue to receive Sandostatin LAR® Depot. The dosage regimen described under Table 4 below does not consider the dosage adjustments made after 2 weeks (see Table 4).

**Patients Currently Receiving Sandostatin® (octreotide acetate) Injection s.c.**

In patients receiving Sandostatin® (octreotide acetate) Injection s.c., in the majority of patients, the half-life of the drug was reduced when switching to Sandostatin LAR® Depot. The dosage regimen described under Table 4 below assumes that patients have not been switched (see Table 4).
Each vial delivers: octreotide acetate 11.2 mg* equivalent to 10 mg octreotide base

Inactive ingredients: D,L-lactic and glycolic acids copolymer 188.8 mg, mannitol 41.0 mg.

FOR INJECTABLE SUSPENSION

STORAGE: Refrigerate at 2 °C - 8 °C (36 °F - 46 °F). Protect from light.

Manufactured for: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936

Warning: Rubber stopper contains LATEX.

Rx only

10 mg
Each vial delivers: octreotide acetate . . . . . . . . . . . . . . . . . . .22.4 mg*
*equivalent to 20 mg octreotide base
Inactive ingredients:
D,L-lactic and glycolic acids copolymer . . 377.6 mg
mannitol . . . . . . . . . . . . . . . . . . . . . . . . .81.9 mg
FOR INJECTABLE SUSPENSION
STORAGE:  Refrigerate at 2 °C - 8 °C (36 °F - 46 °F).  Protect from light.
Manufactured for: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936
Rx only 20mg
NDC 0078-0341-84
Warning: Rubber stopper contains LATEX.
Octreotide acetate . . . . . . . . . . . . . . . . . . .33.6 mg*
*equivalent to 30 mg octreotide base

Inactive ingredients:
D,L-lactic and glycolic acids copolymer . . 566.4 mg
mannitol . . . . . . . . . . . . . . . . . . . . . . . . .122.9 mg

FOR INJECTABLE SUSPENSION

STORAGE:  Refrigerate at 2 °C - 8 °C (36 °F - 46 °F).  Protect from light.

Manufactured for: Novartis Pharmaceuticals
Corporation, East Hanover, NJ 07936

Rx only 30mg
Each vial delivers: octreotide acetate 33.6 mg* equivalent to 30 mg octreotide base
Inactive ingredients:
D,L-lactic and glycolic acids copolymer 566.4 mg
mannitol 122.9 mg
FOR INJECTABLE SUSPENSION
Manufactured for: Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936
WARNING: CONTENTS NOT SUITABLE FOR HUMAN USE.

Warning: Rubber stopper contains LATEX.
Sandostatin LAR® Depot
(octreotide acetate for injectable suspension)

10 mg
FOR INTRAGLUTEAL INJECTION
Rx only
Novartis Pharmaceuticals Corporation
East Hanover, NJ 07936

Diluent for suspension of Sandostatin LAR® Depot
Each syringe contains:
sodium CMC . . . . . . . . . . . . . .12.5 mg
mannitol . . . . . . . . . . . . . . . . .15.5 mg
water for injection . . . . . . . . . . 2.5 mL

STORAGE: Refrigerate at 2-8°C (36°F-46°F).

Rx only
Manufactured for:
Novartis Pharmaceuticals Corporation
East Hanover, NJ 07936

PLEASE PEEL OFF OUTER LAYER AFTER PRODUCT SUSPENSION

Top Section - 072 with knockout
Bottom Section - transparent background

©Novartis
85057801
Diluent for suspension of Sandostatin LAR® Depot
Each syringe contains:
sodium CMC ...................... 12.5 mg
mannitol ........................ 15.0 mg
water for injection ............ 2.5 mL

STORAGE: Refrigerate at 2 °C-8 °C (36 °F-46 °F). Rx only

Manufactured for:
Novartis Pharmaceuticals Corporation
East Hanover, NJ 07936

PLEASE PEEL OFF OUTER LAYER AFTER PRODUCT SUSPENSION

Top Section - 1385 with knockout
Bottom Section - transparent background

Sandostatin LAR® Depot
(Octreotide acetate for injectable suspension)
20 mg
FOR INTRAGLUTEAL INJECTION
Rx only

©Novartis
85059001

Novartis Pharmaceuticals Corporation
East Hanover, NJ 07936
Diluent for Suspension of Sandostatin LAR® Depot

Each syringe contains:
- sodium CMC . . . . . . . . . . . . . .12.5 mg
- mannitol . . . . . . . . . . . . . . . . .15.0 mg
- water for injection . . . . . . . . . . 2.5 mL

STORAGE: Refrigerate at 2 °C - 8 °C (36 °F - 46 °F).

Manufactured for:
Novartis Pharmaceuticals Corporation
East Hanover, NJ 07936

©Novartis
85059101

PLEASE PEEL OFF OUTER LAYER AFTER PRODUCT SUSPENSION

Top Section - 222 with knockout
Bottom Section - transparent background
Suspension

DEMONSTRATION ONLY

Each syringe contains:
- sodium CMC: 12.5 mg
- mannitol: 15.0 mg
- water for injection: 2.5 mL

WARNING: CONTENTS NOT SUITABLE FOR HUMAN USE - DO NOT ADMINISTER

Manufactured for:
Novartis Pharmaceuticals Corporation
East Hanover, NJ 07936

©Novartis 85058901

Top Section - white background
Bottom Section - transparent background
Instruction Booklet

Preparation and Administration of
Sandostatin LAR® Depot
(octreotide acetate for injectable depot)

Read this entire booklet before proceeding. If you have questions about preparation and/or administration of Sandostatin LAR® Depot, please call 1-877-LAR-HELP (1-877-527-4357).

ATTENTION:
- Follow enclosed instruction booklet precisely
- Administer immediately after suspension
- Use only 1 1/2" 19 gauge needles
- If needle clogs, replace with a new 1 1/2" 19 gauge needle

Incorrect preparation and/or administration could result in failure of drug delivery.

WARNING: Rubber stopper on vial contains LATEX.

Step 7
- Peel off outer syringe label

Step 8
- Immediately fill the syringe with air, insert the needle through the rubber stopper, and slowly inject all of the air into the vial
- With the bevel down and the vial tipped at approximately a 45-degree angle (as shown in the diagram), slowly draw the entire contents into the vial without inverting vial
- Some residual suspension will remain – vial contains overfill

Step 9
- Draw a small amount of air into the syringe to allow the suspended product to move more freely
- Rock the syringe gently and constantly to maintain a uniform suspension
- Eliminate air from syringe
- Change the needle, discarding the first needle and attaching the second supplied needle

Step 10
- Prepare the injection site with the supplied alcohol wipe
- Rock the syringe gently and constantly to maintain a uniform suspension
- Insert needle deep into right or left gluteus and draw back to ensure that no blood vessel has been penetrated. (If a blood vessel has been penetrated, attach a new 1 1/2" 19 gauge needle and select another injection site)
- Immediately inject contents of entire syringe IM
- If needle clogs, replace with a new 1 1/2" 19 gauge needle
- Note: Record injection site on patient’s record and alternate monthly
Instructions for Intramuscular (IM) Injection of Sandostatin LAR® Depot (octreotide acetate for injectable suspension)

Important Information for Healthcare Professionals

Successful preparation and administration of Sandostatin LAR® Depot relies on proper suspension technique. Follow each of the steps outlined in this instruction booklet to ensure complete saturation of the powder and its uniform suspension prior to deep intragluteal injection.

It is recommended that Sandostatin LAR® Depot and the diluent be allowed to reach room temperature and then be mixed immediately prior to injection. Ensure that the powder is completely suspended at the time of injection.

If you have questions about preparation and/or administration of Sandostatin LAR® Depot, please call 1-877-LAR-HELP (1-877-527-4357).

For more information on Sandostatin LAR® Depot, see the enclosed full prescribing information.

Package Contents
- Vial containing Sandostatin LAR® Depot
- Syringe containing diluent
- Two 1½” 19 gauge needles
- Two alcohol wipes

Step 1
- Allow the vial containing Sandostatin LAR® Depot and the diluent syringe to reach room temperature (approximately 30 to 60 minutes)

Step 2
- Remove the cap from the diluent syringe
- Attach one of the supplied needles to the syringe
- Use only 1½” 19 gauge needles
- Do not directly inject diluent without preparing suspension

Step 3
- Gently tap the Sandostatin LAR® Depot vial to ensure that all powder has settled to the bottom
- Clean the Sandostatin LAR® Depot vial stopper with supplied alcohol wipe

Step 4
- Insert the needle through the center of the rubber stopper of the Sandostatin LAR® Depot vial
- Without disturbing the Sandostatin LAR® Depot powder, gently inject contents of syringe down the inside wall of the vial
- Remove syringe from vial
- Retain the syringe for further use in Step 7

Step 5
- Do not disturb the vial while diluent saturates the Sandostatin LAR® Depot powder (approximately 5 minutes)
- After 5 minutes, without inverting vial, check sides and bottom of vial for dry spots
- Powder must be completely saturated before proceeding
- If dry spots exist, allow wetting to continue and check vial every 30 seconds until saturation is complete

Step 6
- Once complete saturation has occurred, swirl the vial moderately for 30 to 60 seconds or until a uniform suspension is achieved
- Do not shake or invert the vial
- The suspension will be milky

Step 7
- Gently tap the Sandostatin LAR® Depot vial to ensure that all powder has settled back to the bottom
- Clean the Sandostatin LAR® Depot vial stopper with supplied alcohol wipe
- Retain the syringe for further use in Step 7
<table>
<thead>
<tr>
<th>Used Colours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black (100% 45%)</td>
</tr>
<tr>
<td>PMS 320 (100%, 70%, 40%, 10%)</td>
</tr>
<tr>
<td>PMS 179</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Made by</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dianne Ligthart</td>
</tr>
</tbody>
</table>
Step 7

- Peel off outer syringe label

Step 8

- Immediately fill the syringe with air, insert the needle through the rubber stopper, and slowly inject all of the air into the vial
- With the bevel down and the vial tipped at approximately a 45-degree angle (as shown in the diagram), slowly draw the entire contents into the syringe without inverting the vial
- Some residual suspension will remain – vial contains overfill

Step 9

- Draw a small amount of air into the syringe to allow the suspended product to move more freely
- Rock the syringe gently and constantly to maintain a uniform suspension
- Eliminate air from syringe
- Change the needle, discarding the first needle and attaching the second supplied needle

YOU HAVE NOW COMPLETED THE TRAINING FOR PREPARATION OF THE SANDOSTATIN LAR® DEPOT USING THE DILUENT SYRINGE.

WARNING:
THE CONTENTS OF THE DEMONSTRATION KIT ARE NOT SUITABLE FOR HUMAN USE.

SYRINGE CONTENTS AND NEEDLES SUPPLIED IN THE DEMONSTRATION KIT SHOULD BE DISCARDED IN A SAFE MANNER.
This instruction booklet is being provided as part of a demonstration kit to educate healthcare providers on the proper technique to be employed when reconstituting Sandostatin LAR® Depot (octreotide acetate for injectable suspension) with the diluent syringe.

Important Information for Healthcare Professionals

Successful preparation of Sandostatin LAR® Depot relies on proper suspension technique.

Follow each of the steps outlined in this instruction booklet to ensure complete saturation of the powder and its uniform suspension.

It is recommended that Sandostatin LAR® Depot and the diluent be allowed to reach room temperature and then be mixed to ensure that the powder is completely suspended.

If you have questions about preparation of Sandostatin LAR® Depot, please call 1-877-LAR-HELP (1-877-527-4357).

For more information on Sandostatin LAR® Depot, see the enclosed full prescribing information.

Package Contents
• Vial containing Sandostatin LAR® Depot
• Syringe containing diluent
• Two 11/2" 19 gauge needles
• Two alcohol wipes

Step 1
• Allow the vial containing Sandostatin LAR® Depot and the diluent syringe to reach room temperature (approximately 30 to 60 minutes)
• Remove the plastic cap from the vial

Step 2
• Remove the cap from the diluent syringe
• Attach one of the supplied needles to the syringe
• Use only 11/2” 19 gauge needles

Step 3
• Gently tap the Sandostatin LAR® Depot vial to ensure that all powder has settled to the bottom
• Clean the Sandostatin LAR® Depot vial stopper with supplied alcohol wipe

Step 4
• Insert the needle through the center of the rubber stopper of the Sandostatin LAR® Depot vial
• Without disturbing the Sandostatin LAR® Depot powder, gently inject contents of syringe down the inside wall of the vial
• Remove syringe from vial
• Retain the syringe for further use in Step 7

Step 5
• Do not disturb the vial while diluent saturates the Sandostatin LAR® Depot powder (approximately 5 minutes)
• After 5 minutes, without inverting vial, check sides and bottom of vial for dry spots
• Powder must be completely saturated before proceeding
• If dry spots exist, allow wetting to continue and check vial every 30 seconds until saturation is complete

Step 6
• Once complete saturation has occurred, swirl the vial moderately for 30 to 60 seconds or until a uniform suspension is achieved
• Do not shake or invert the vial
• The suspension will be milky
SAP-number: 1027577/ 0  replaces in time: -
print date: 23-10-2003
die cut/dimension: 127 x 76
pharma code: 112
used colours: black, PMS 320, PMS 179
file name: 1027577.SAN.DEMO.BK.US
made by: Dianne Ligthart
ATTENTION:
• Follow enclosed instruction booklet precisely
• Administer immediately after suspension
• Use only 1 1/2” 19 gauge needles
• If needle clogs, replace with a new 1 1/2” 19 gauge needle
Incorrect preparation and/or administration could result in failure of drug delivery.

WARNING: Rubber stopper on vial contains LATEX.

Contents:
• Vial containing Sandostatin LAR® Depot
• Syringe containing diluent
• Two 1 1/2” 19 gauge needles
• Two alcohol wipes

Rx only

Sandostatin LAR® Depot
(octreotide acetate for injectable suspension)

©Novartis 85057901

PMS 179
PMS 320 (100% in logo)
PMS 320 (10% in logo)
PMS 320 (40% in logo)
PMS 320 (70% in logo)
PMS 072 (100%)
PMS 072 (40%)
Black

Do not print dotted lines (FPO) For Position Only
ATTENTION:
• Follow enclosed instruction booklet precisely
• Administer immediately after suspension
• Use only 1½” 19 gauge needles
• If needle clogs, replace with a new 1½” 19 gauge needle
Incorrect preparation and/or administration could result in failure of drug delivery.

Contents:
• Vial containing Sandostatin LAR® Depot
• Syringe containing diluent
• Two 1½” 19 gauge needles
• Two alcohol wipes

WARNING: Rubber stopper on vial contains LATEX.
ATTENTION:
• Follow enclosed instruction booklet precisely
• Administer immediately after suspension
• Use only 1 1/2” 19 gauge needles
• If needle clogs, replace with a new 1 1/2” 19 gauge needle
Incorrect preparation and/or administration could result in failure of drug delivery.

WARNING: Rubber stopper on vial contains LATEX.

Contents: • Vial containing Sandostatin LAR® Depot
• Syringe containing diluent
• Two 1 1/2” 19 gauge needles
• Two alcohol wipes

30mg Sandostatin LAR® Depot
(octreotide acetate for injectable suspension)

Rx only

©Novartis 85058001
DEMONSTRATION ONLY

Contents: • Vial containing Sandostatin LAR® Depot
• Syringe containing diluent
• Two 1½" 19 gauge needles
• Two alcohol wipes

ATTENTION:
• CONTENTS NOT SUITABLE FOR HUMAN USE
• THIS KIT IS FOR PREPARATION TRAINING ONLY
• USE ONLY 1½" 19 GAUGE NEEDLES
• DO NOT ADMINISTER THE CONTENTS OF THIS KIT